Kelvin®

Developing Al-oriented digital tool for screening & monitoring of early stage breast cancer

Partnering with Novartis Oncology, MORE-Darzalas and multiple HCP's to **reduce breast cancer undercare via** <u>personalized</u> mobile thermography AI

kelvin.health | **info@kelvin.health** October, 2021



The Breast Cancer Pandemic



women will develop



newly diagnosed and 685K deaths globally in 2020



alive who were diagnosed in the past 5 years





In Practice

would benefit from regular screening to increase chances of early detection

lives can be saved annually thanks to early detection

at Stage I before metastasis

mammograms / year

need to be examined currently when monitoring the survivors

kelvin



Kelvin Health's Mobile Thermography



Mobile Thermocamera

Captures the heat emitted by the body



Al Analysis Thermal Segmentation

Proprietary segmentation of the thermal image

Machine-learning based detection of anomalies

Compared to existing screening & monitoring approaches this one is:



Widely accessible and personalized



Appropriate for frequent application, even to pregnant women



Applicable to dense breast tissue (as in younger women)



Portable and allowing remote self-application initially



Causing minimal physical, logistical, and financial discomfort

kelvin





Some of Our Screening Samples







Another Major Application - CVD Care



Thrombophlebitis / VTE / DVT Screening & Monitoring

(**10M+ people** worldwide suffering VTE)

iy→ kelvin[®]



PVD / PAD Screening & Treatment Effect Monitoring

(200M+ people worldwide suffering PAD)



Even More Potential Applications



Rheumatoid Arthritis (autoimmune inflamantons)

Traumatology (in ER context)







COVID-19 (respiratory infections monitoring)



Value Prop to Consumers & Payers

Enabling screening in the comfort of your home or local primary care hub:

- Less psychological and financial stress
- Less exposure to radiation
- More **convenient logistics**
- More frequent and personalized screening



Ultimately, **better health outcomes** and **significant cost savings** thanks to earlier detection of eventual problems.



Treatment Costs for Breast Cancer

Costs allowed per patient in the 24 months after the index diagnosis: Stage 0: **\$71,909** Stage I/II: **\$97,066** Stage III: **\$159,442** Stage IV: **\$182,655**

Knowledge of the relevant stagespecific cost data provides support for programs, such as breast cancer screening, that are designed to shift diagnosis to earlier disease stages.





Market Access Value Prop to Pharma

Enabling wider market access to breast cancer patients, as:



More patients will be diagnosed early and enter the patient journey;



Ineffective treatment will be detected earlier, investigated and adjusted properly without the need to switch the patient therapy off;



The demographic segments that respond best to the therapy will be identified, making it a **preferred choice of payers** (insurers, national health systems).



"The Kelvin Health projected solution in Oncology would add tremendous value to the level of our services by providing new disruptive, quickly and easily accessible technology solution supporting processes for improvement of health status in oncology care."

– Ivaylo Petrov **Innovation & Transformation Central** Eastern Europe Lead, Market Access Lead - Novartis Oncology





Current Progress



Technology Implementations:

Machine Learning and Software Backend Toolchains and infrastructure properly set up

Mobile Application For Thermal Data Collection Currently working with iOS and Flir One Pro thermal camera

Evaluation of OEM Thermal Hardware Options

Specification and planning of collaboration with vendors

Pharmaceutical R&D Collaborations:



Novartis Oncology Region Europe / BIOME Innovation Lab Research collaboration projects

Winner of Novartis Oncology Global Challenge "Braking Barriers" '21



Cancer Research R&D Collaborations:

MORE-Darzalas Foundation Mass screening for Breast Cancer in Bulgaria



Regulatory Approvals:

Ministry of Health Thermography research clearance

Data Protection Agency Thermography data clearance

Drug Agency Cancer research clearance (in progress)



HCP's R&D Collaborations:

University Clinical Centre Maribor Screening for Breast Cancer in Slovenia

1st GH "St. Sofia"

Screening for Breast Cancer in Bulgaria

"We are already in partnership with Kelvin Health Inc. in MVP phase of concept in Breast Cancer diagnostic together with Novartis Region Europe Medical department and "Darzalas" Foundation testing healthcare solutions to our customers. We work on strategic project in oncology in order to develop and implement e-health and telemonitoring solutions in European healthcare system."



Innovation & Transformation Central Eastern Europe Lead, Market Access Lead - **Novartis Oncology**





R&D Phase





Commercialization Phase

Unique Opportunity



team experience pioneers in image recognition, processed >26B generic images

Data

unique thermal set

will be created in an accessible regulatory environment (CEE)

renc

preventive medicine that is personalized, precise, rapid, and using the wave of telemedicine and global fight against cancer



kelvin[®]

We believe that a true Unicorn should positively impact the lives of 1B+ people. That's why we are working relentlessly to help preventing the suffering of half billion women and their families.

We would love to have you as a partner on this journey in case we share the same values!

kelvin.health | info@kelvin.health October, 2021

